新闻中心

公司动态

China's Nuance Biotech Options Two Cancer Treatments From Celleron

11 01 2016




Nuance Biotech of Shanghai has acquired an option from Oxford's Celleron Therapeutics for rights to two Celleron clinical-stage cancer treatments in Greater China and South Africa. The two companies will conduct clinical trials of the Celleron assets in Oxford, China and South Africa. Nuance will make upfront, development and regulatory milestone payments to Celleron, and it will be responsible for all development and commercialization expenses in its territories.


关注我们
不良反应反馈邮箱:drugsafety@nuancebiotech.cn Copyright 2017-2019 优锐医药. 网站建设备案号:沪ICP备17029781号
地址: 上海市黄浦区南京西路388号仙乐斯广场2106室 邮箱: info@nuancebiotech.cn 电话: 021-32035318
  • 首页
  • 电话
  • 留言